Arch Biopartners Inc (ARCH : TSX-V)
Common Stock
$0.49
CAD
-0.03 (-5.77%)
Last updated: 2026-06-02
ARCH
Arch Biopartners Inc
WealthAwesomePerformance
1 Day
-5.77%
1 Week
+10.11%
1 Month
+12.64%
YTD
-60.80%
Key Statistics
Market Cap
$32.61M
52W High
$1.95
52W Low
$0.39
P/E Ratio
-
50 Day MA
$0.49
200 Day MA
$1.01
Beta
2.05
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/2/2026 | $0.54 | $0.54 | $0.48 | $0.49 | $0.49 | 41,256 |
| 6/1/2026 | $0.45 | $0.53 | $0.45 | $0.52 | $0.52 | 51,620 |
| 5/29/2026 | $0.45 | $0.45 | $0.43 | $0.45 | $0.45 | 68,700 |
| 5/28/2026 | $0.45 | $0.45 | $0.44 | $0.45 | $0.45 | 18,300 |
| 5/27/2026 | $0.45 | $0.45 | $0.45 | $0.45 | $0.45 | 19,363 |
| 5/26/2026 | $0.45 | $0.45 | $0.45 | $0.45 | $0.45 | 3,264 |
| 5/25/2026 | $0.45 | $0.45 | $0.45 | $0.45 | $0.45 | 11,464 |
| 5/22/2026 | $0.45 | $0.45 | $0.45 | $0.45 | $0.45 | 33,884 |
| 5/21/2026 | $0.45 | $0.45 | $0.42 | $0.45 | $0.45 | 29,000 |
| 5/20/2026 | $0.44 | $0.45 | $0.43 | $0.45 | $0.45 | 10,199 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARCH's historical volatility
30-Day Vol
85.4%
Annualized
90-Day Vol
100.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.46 | C$0.34 – C$0.62 |
| 60 trading days | C$0.44 | C$0.29 – C$0.66 |
| 90 trading days | C$0.41 | C$0.25 – C$0.68 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Financials
- Revenue (TTM)
- $158,079
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- 0.00%
- EPS (Diluted)
- -0.04
- Book Value
- -0.05
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About ARCH
Articles Featuring ARCH.V
Latest articles and analysis covering ARCH.V
![10 Best Canadian Biotech Stocks ([currentmonthyear])](https://lhajohzwizrsjmumhpjg.supabase.co/storage/v1/object/public/wealth-awesome/site-media/best-canadian-biotech-stocks_8-1.jpg)